Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Added Value of HR-pQCT in Detecting Calcium Deposits in Rheumatoid Arthritis (HAND-QCT-RA)

16 de noviembre de 2026 actualizado por: Istituto Ortopedico Rizzoli

Added Value of HR-pQCT: Detecting and Characterizing Calcium Deposits Suggestive of CPPD in the Hand and Wrist of Rheumatoid Arthritis Patients (HAND-QCT-RA)

The goal of this clinical trial is to learn if a high-resolution computed tomography scan (HR-pQCT) can detect and describe calcium crystal deposits in the hands and wrists of adults with rheumatoid arthritis (RA). The main questions it aims to answer are:

  • How often does the HR-pQCT scan detect calcium crystal deposits in the hand and wrist joints of people with RA?
  • Can the HR-pQCT scan find calcium deposits that standard tests (x-rays and ultrasound) miss? Researchers will compare scan results from participants with RA to results from participants with known calcium pyrophosphate deposition (CPPD) and participants without joint inflammation.

During a single clinic visit, participants will:

  • Have standard x-rays of their hands and wrists
  • Have a routine ultrasound of their hands and wrists
  • Have an HR-pQCT scan of their wrist and finger joints, which takes about 15 to 20 minutes and uses a very low dose of radiation

Descripción general del estudio

Descripción detallada

Calcium pyrophosphate deposition (CPPD) disease is an underdiagnosed crystal arthritis that frequently mimics rheumatoid arthritis (RA) or coexists with it, particularly when presenting as chronic inflammatory polyarthritis involving the wrists and metacarpophalangeal (MCP) joints. Although synovial fluid crystal identification remains the reference standard, aspiration of small hand joints is often technically unfeasible or non-diagnostic. Consequently, diagnosis relies heavily on conventional radiography and musculoskeletal ultrasonography, both of which suffer from recognized limitations in detecting subtle or early calcifications.

High-resolution peripheral quantitative computed tomography (HR-pQCT) provides superior spatial resolution and volumetric bone microarchitecture assessment. This multicenter, cross-sectional pilot study investigates whether HR-pQCT can enhance the detection and structural characterization of CPPD-suggestive calcium deposits within the triangular fibrocartilage complex (TFCC) and 2nd/3rd MCP hyaline cartilage.

To enable combined multi-site analysis, cross-calibration between the two participating tertiary centers (IRCCS Istituto Ortopedico Rizzoli, utilizing a second-generation Scanco XtremeCT II system, and AOUI Verona, utilizing a RAR Medical Devices ArtiCAT cone-beam system) is conducted using the European Forearm Phantom (EFP; QRM AG). Scans follow harmonized volumetric acquisition protocols based on international recommendations (SPECTRA group). All imaging acquisitions (radiographs, ultrasound, and HR-pQCT) are evaluated independently and in a double-blinded manner by trained musculoskeletal radiologists and rheumatologists.

At the patient level, a participant is classified as positive if at least one calcium deposit is detected in any of the examined joints. Because each participant undergoes imaging across multiple anatomical sites (the TFCC of the wrist and the 2nd and 3rd metacarpophalangeal joints of both hands), observations from the same individual are correlated. To account for this within-subject correlation without losing anatomical detail, site-specific analyses will be conducted using mixed-effects models or generalized estimating equations (GEE).

Tipo de estudio

Intervencionista

Inscripción (Estimado)

140

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Jacopo Ciaffi
  • Número de teléfono: +39 051.6445505
  • Correo electrónico: jacopo.ciaffi@ior.it

Ubicaciones de estudio

    • Bologna
      • Bologna, Bologna, Italia, 40136
        • IRCCS Istituto Ortopedico Rizzoli - SSD Medicina e Reumatologia
    • Verona
      • Verona, Verona, Italia, 37134
        • Azienda Ospedaliera Universitaria Integrata di Verona - UO di Reumatologia

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

60 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Rheumatoid Arthritis (RA) Cohort:

  • Age ≥ 60 years
  • Diagnosis of Rheumatoid Arthritis according to 2010 ACR/EULAR classification criteria
  • Clinical diagnosis confirmed by an expert rheumatologist
  • Current or past inflammatory involvement of the hand and/or wrist
  • Written informed consent obtained

Calcium Pyrophosphate Deposition (CPPD) Cohort:

  • Age ≥ 60 years
  • Established diagnosis of CPPD based on synovial fluid crystal analysis and/or imaging findings compatible with current classification criteria
  • Current or past inflammatory involvement of the hand and/or wrist
  • Written informed consent obtained

Control Cohort (Non-inflammatory Controls):

  • Age ≥ 60 years
  • Outpatient evaluation at one of the participating centers for a condition not suggestive of CPPD, rheumatoid arthritis, erosive osteoarthritis, or other inflammatory joint diseases
  • Clinical indication for conventional radiography of the hand and/or wrist as part of routine clinical practice
  • Absence of past or present hand or wrist joint swelling suggestive of inflammatory arthritis
  • Written informed consent obtained

Exclusion Criteria:

All Cohorts:

  • Contraindications to CT-based imaging (including the inability to immobilize the hand and wrist during image acquisition)
  • Known causes of secondary CPPD (e.g., hyperparathyroidism, hemochromatosis, hypomagnesemia, hypophosphatasia)
  • Presence of hand/wrist prosthesis or osteosynthesis material interfering with image acquisition
  • Inability to provide written informed consent

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Rheumatoid Arthritis (RA) Cohort

Patients with RA and current or prior hand/wrist involvement (n = 60).

High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.

Otros nombres:
  • HR-pQCT
  • Scanco XtremeCT II
  • RAR Medical Devices ArtiCAT cone-beam
Comparador activo: Healthy / Non-inflammatory Controls

Subjects undergoing hand/wrist imaging for non-inflammatory conditions (n = 60).

High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.

Otros nombres:
  • HR-pQCT
  • Scanco XtremeCT II
  • RAR Medical Devices ArtiCAT cone-beam
Comparador activo: CPPD Positive Control Cohort

Patients with proven CPPD disease (n = 20).

High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.

Otros nombres:
  • HR-pQCT
  • Scanco XtremeCT II
  • RAR Medical Devices ArtiCAT cone-beam

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in rheumatoid arthritis
Periodo de tiempo: Baseline (single imaging visit)

Percentage of participants with rheumatoid arthritis with at least one calcium deposit suggestive of CPPD detected by HR-pQCT at the triangular fibrocartilage complex (TFCC) and/or the 2nd-3rd metacarpophalangeal (MCP) joints.

Baseline (single imaging visit)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of HR-pQCT-positive cases missed by conventional imaging
Periodo de tiempo: Baseline (single imaging visit)

Percentage of participants with no CPPD-suggestive calcium deposits on either conventional radiography or ultrasonography who have at least one CPPD-suggestive calcium deposit on HR-pQCT.

Baseline (single imaging visit)
Agreement between conventional radiography and HR-pQCT for CPPD-suggestive calcium deposits
Periodo de tiempo: Baseline (single imaging visit)

Cohen's kappa coefficient for agreement between conventional radiography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits.

Baseline (single imaging visit)
Agreement between ultrasonography and HR-pQCT for CPPD-suggestive calcium deposits
Periodo de tiempo: Baseline (single imaging visit)

Cohen's kappa coefficient for agreement between ultrasonography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits.

Baseline (single imaging visit)
Agreement between combined conventional imaging and HR-pQCT for CPPD-suggestive calcium deposits
Periodo de tiempo: Baseline (single imaging visit)

Cohen's kappa coefficient for agreement between combined conventional imaging and HR-pQCT. A participant is classified as positive on combined conventional imaging if deposits are detected on radiography, ultrasonography, or both.

Baseline (single imaging visit)
Volume of CPPD-suggestive calcium deposits on HR-pQCT
Periodo de tiempo: Baseline (single imaging visit)

Total volume of CPPD-suggestive calcium deposits per participant, measured on HR-pQCT (mm³), in participants with at least one deposit.

Baseline (single imaging visit)
Volumetric density of CPPD-suggestive calcium deposits on HR-pQCT
Periodo de tiempo: Baseline (single imaging visit)

Mean volumetric density of CPPD-suggestive calcium deposits (mg HA/cm³), measured on HR-pQCT, in participants with at least one deposit.

Baseline (single imaging visit)
Anatomical distribution of CPPD-suggestive calcium deposits on HR-pQCT
Periodo de tiempo: Baseline (single imaging visit)

Percentage of participants with deposits at the TFCC only, at the 2nd-3rd MCP joints only, or at both sites, among participants with at least one deposit on HR-pQCT.

Baseline (single imaging visit)

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in seronegative vs seropositive rheumatoid arthritis
Periodo de tiempo: Baseline (single imaging visit)

Percentage of participants with at least one CPPD-suggestive calcium deposit on HR-pQCT, reported separately for seronegative participants (RF- and ACPA-negative) and seropositive participants.

Baseline (single imaging visit)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de enero de 2027

Finalización primaria (Estimado)

30 de abril de 2029

Finalización del estudio (Estimado)

31 de octubre de 2029

Fechas de registro del estudio

Enviado por primera vez

6 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir